Arbor Biotechnologies

Venture-backed company · Stage unknownarbor.bio

At Arbor Biotechnologies, we develop genetic medicines through our discovery of programmable DNA editors to enable curative outcomes for patients.

Rounds on record
1
Latest round
Oct 29, 2021
Form D equity offering
Latest round size
$215M
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

3 additional investors

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. 5 investors
    named

    5 investors on record.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
Drawing the relationship network…

Facts

Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
5

Financing history

1 round
  1. Oct 29, 2021
    Form D equity offering · $215M (form d sold)
    Arch Venture Partners via Keith Lawrence Crandell
    Fact Form D · “Arbor Biotechnologies, Inc. Form D, first filed 2021-11-10”

Investors on record

6 edges

Ownership and outcomes

none on record
Outcome stated by investors

Listed on 5 firm portfolio pages; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.

Evidence: 5 listingseach firm's own card, as read
  • Status not stated on Arch Venture Partners · the firm's card prints no outcome · read Sep 30, 2026 archventure.com
    “Arbor Biotechnologies”
  • Status not stated on Addition, L.P. · the firm's card prints no outcome · read Sep 25, 2026 arbor.bio
    “In addition to his operating roles, Don brings valuable governance experience, serving on the Boards of Aspect Biosystems, Immvention Therapeutix (as Chairman), and Orthox Ltd.”
  • Status not stated on Driven, LLC · the firm's card prints no outcome · read Sep 25, 2026 arbor.bio
    “United by this shared vision and driven by a passion to deliver for patients, we have amassed one of the most talented and dedicated teams in the field to continue building upon the groundbreaking wor”

2 more listings counted above; the firms are named with a plan.

No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.

Credit relationships

none on record
No lender position matched to this company.

People

0 officers, 0 directors
No officer or director on record.

Timeline

0 events
No dated event on record.

Evidence

7 observations
Every observation on this company
  • Description: Sep 25, 2026 Fact
  • Investors named on site: 4 Sep 25, 2026 Fact
  • Listed on portfolio page: Sep 30, 2026 Fact
  • Listed on portfolio page: Sep 16, 2026 Fact
  • Listed on portfolio page: Sep 14, 2026 Fact
  • Website status: ok Sep 25, 2026 Fact
  • Site title: Sep 25, 2026 Fact

Relationships across DFX

on 1 other DFX graph · 11 capital paths
Across the graphs

Arbor Biotechnologies is the same institution as 1 record in Private Equity.

Private Equity1

The joined record opens with the product, beside every other relationship on this page.

Checking your plan…

Capital chain

Arbor Biotechnologies sits on 11 traced paths of capital across the graphs.

Allocator to VC fund to manager to company

DFX traced 11 paths of capital through this record

Every record on each path, what it committed or lent, and as of when.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Derived from allocator disclosures, BDC schedules and SEC filings; confidence is the weakest hop.

Checking your plan…